TY - JOUR AU - Balakrishnan, Karthikeyan AU - Rijal Upadhaya, Ajeet AU - Steinmetz, Julia AU - Reichwald, Julia AU - Abramowski, Dorothee AU - Fändrich, Marcus AU - Kumar, Sathish AU - Yamaguchi, Haruyasu AU - Walter, Jochen AU - Staufenbiel, Matthias AU - Thal, Dietmar Rudolf PY - 2015 DA - 2015/07/04 TI - Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice JO - Acta Neuropathologica Communications SP - 41 VL - 3 IS - 1 AB - The deposition of the amyloid β protein (Aβ) in the brain is a hallmark of Alzheimer's disease (AD). Removal of Aβ by Aβ-antibody treatment has been developed as a potential treatment strategy against AD. First clinical trials showed neither a stop nor a reduction of disease progression. Recently, we have shown that the formation of soluble and insoluble Aβ aggregates in the human brain follows a hierarchical sequence of three biochemical maturation stages (B-Aβ stages). To test the impact of the B-Aβ stage on Aβ immunotherapy, we treated transgenic mice expressing human amyloid precursor protein (APP) carrying the Swedish mutation (KM670/671NL; APP23) with the Aβ-antibody β1 or phosphate-buffered saline (PBS) beginning 1) at 3 months, before the onset of dendrite degeneration and plaque deposition, and 2) at 7 months, after the start of Aβ plaque deposition and dendrite degeneration. SN - 2051-5960 UR - https://doi.org/10.1186/s40478-015-0217-z DO - 10.1186/s40478-015-0217-z ID - Balakrishnan2015 ER -